Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Cash from Financing Activities (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Cash from Financing Activities for 7 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 45.24% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $478.0 million, a 6079.54% increase, with the full-year FY2025 number at $478.0 million, up 6079.54% from a year prior.
  • Cash from Financing Activities was $1.9 million for Q4 2025 at Beam Therapeutics, up from $1.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $473.4 million in Q1 2025 to a low of $133000.0 in Q2 2024.
  • A 5-year average of $81.5 million and a median of $27.2 million in 2022 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 341268.09% in 2021, then crashed 99.88% in 2024.
  • Beam Therapeutics' Cash from Financing Activities stood at $21.5 million in 2021, then surged by 48.6% to $32.0 million in 2022, then grew by 5.31% to $33.7 million in 2023, then tumbled by 89.78% to $3.4 million in 2024, then plummeted by 45.24% to $1.9 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Cash from Financing Activities are $1.9 million (Q4 2025), $1.7 million (Q3 2025), and $1.1 million (Q2 2025).